Howard Wu
Co-Founder & Chief Scientific Officer Full Circles Therapeutics
Seminars
Tuesday 29th September 2026
Engineering Tripartite Cas9-ssDNA Binding Fusion Proteins to Enhance Non-Viral Targeted Genome Integration for Therapeutic Applications
3:30 pm
- Developing enGager system by fusing nuclear-localized Cas9 with ssDNA-binding motifs to achieve up to 6-fold higher integration efficiency
- Demonstrating CAR transgene integration in 33% of primary human T cells using non-viral cssDNA donors to enhance anti-tumor functionality safely
- Validating compact 20-amino acid RecA L2 ssDNA-binding motifs as alternatives to recombination proteins to improve HDR-mediated genome integration
